Cuban vaccine Abdala has high efficacy rate in serious COVID-19 patients

Eldonita de Ed Newman
2021-09-22 13:40:06

Pinterest
Telegram
Linkedin
WhatsApp

The Center for Genetic Engineering and Biotechnology (CIGB) reported that its Abdala Covid-19 vaccine has an efficacy rate of 90%

Havana, September 22 (RHC/Prensa Latina) The Center for Genetic Engineering and Biotechnology (CIGB) reported that its Abdala Covid-19 vaccine has an efficacy rate of 90% in seriously ill patients affected by the SARS-CoV-2 virus, according to local media.

The daily newspaper Granma, reported that in July the vaccine was granted authorization for emergency use, after demonstrating 92.28% efficacy in preventing symptoms of the disease.

The latest achievement by the CIGB comes as the aggressive Delta variant of the SARS-COV-2 virus continues to spread on the island. 

'Efficacy should not be confused with effectiveness, since the former is determined in controlled clinical trials, that is, under ideal research conditions; while effectiveness relates to how well the vaccine works in real life, clarified CIGB Director General, Marta Ayala.

Scientists from the CIGB and the Finlay Vaccine Institute - which developed the Soberana 02 and Soberana Plus jabs - recently presented their research, process and development results to the World Health Organization in hopes that the body will approve the vaccines for international use.



Komentarioj


Lasu komentarion
Ĉiuj kampoj bezonatas
Ne estos publikigita
captcha challenge
up